Your browser doesn't support javascript.
loading
Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review.
Qureshi, Zaheer; Jamil, Abdur; Altaf, Faryal; Siddique, Rimsha; Adilovic, Edin; Fatima, Eeshal; Shah, Shivendra.
Afiliación
  • Qureshi Z; The Frank H. Netter M.D. School of Medicine at Quinnipiac University.
  • Jamil A; Department of Medicine, Samaritan Medical Centre.
  • Altaf F; Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/BronxCare Health System, New York, NY, USA.
  • Siddique R; Independent Research Associate, Watertown.
  • Adilovic E; St. Vincent Medical Center, Bridgeport, CT.
  • Fatima E; Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan.
  • Shah S; Department of Medicine, Nepalgunj Medical College, Chisapani, Nepal.
Ann Med Surg (Lond) ; 86(8): 4624-4633, 2024 Aug.
Article en En | MEDLINE | ID: mdl-39118705
ABSTRACT

Introduction:

Estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer with ESR1 mutations presents a significant therapeutic challenge due to its adaptive resistance mechanisms to chemotherapy, especially endocrine treatment. Elacestrant, a novel oral selective estrogen receptor degrader (SERD), has emerged as a promising agent in this treatment-resistant era.

Method:

A comprehensive search was conducted on pivotal clinical trials, including the RAD1901-005 Trial, EMERALD TRIAL, ELIPSE, and ELEVATE, focusing on their methodologies, patient populations, treatment regimens, and outcomes.

Discussion:

This narrative review describes the available preclinical and clinical evidence on elacestrant, focusing on its pharmacodynamics, pharmacokinetics, efficacy, and safety within the existing literature. Elacestrant has demonstrated excellent activity against ESR1 mutations associated with resistance to first-line endocrine therapies. Clinical trials have shown improved progression-free survival in patients with advanced ER+/HER2-, ESR1-mutated breast cancer. Safety profiles indicate a tolerable side effect spectrum consistent with other agents. Its oral bioavailability offers a convenient alternative to injectable SERDs, with potential implications for patient adherence and quality of life. The review also discusses the comparative efficacy of elacestrant relative to existing endocrine therapies and its possible use in combination regimens.

Conclusion:

Ongoing clinical trials assessing elacestrant and other SERDs will yield data that might aid clinicians in determining the optimal selection and order of endocrine treatment drugs for ER+ breast cancer. The integration of targeted and immunotherapeutic agents with traditional chemotherapy represents a pivotal shift in Breast Cancer treatment, moving towards more personalized and effective regimens.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Med Surg (Lond) Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Med Surg (Lond) Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido